Israel Englander’s Elicio Therapeutics ELTX Stock Holding History

Israel Englander’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-92,762	Closed	-$992K	–	5996
2026 Q1	$992K	Buy	+92,762	New	+$896K	﹤0.01%	4398
2025 Q4	–	Sell	-22,846	Closed	-$250K	–	6104
2025 Q3	$250K	Buy	+22,846	New	+$231K	﹤0.01%	5434
2025 Q2	–	Sell	-52,218	Closed	-$322K	–	5971
2025 Q1	$322K	Buy	+52,218	New	+$404K	﹤0.01%	5063
2023 Q4	–	Sell	-20,380	Closed	-$172K	–	6185
2023 Q3	$172K	Buy	+20,380	New	+$194K	﹤0.01%	5178
2023 Q2	–	Sell	-6,937	Closed	-$40K	–	6227
2023 Q1	$40K	Sell	6,937 -597	-8%	-$3.98K	﹤0.01%	5688
2022 Q4	$61K	Sell	7,534 -5,026	-40%	-$45.7K	﹤0.01%	5726
2022 Q3	$116K	Sell	12,560 -5,781	-32%	-$60.4K	﹤0.01%	5915
2022 Q2	$209K	Buy	+18,341	New	+$293K	﹤0.01%	5609
2022 Q1	–	Sell	-6,264	Closed	-$182K	–	7038
2021 Q4	$182K	Buy	+6,264	New	+$317K	﹤0.01%	5978
2021 Q3	–	Sell	-4,806	Closed	-$626K	–	6889
2021 Q2	$626K	Buy	4,806 +1,480	+44%	+$213K	﹤0.01%	5104
2021 Q1	$601K	Buy	+3,326	New	+$642K	﹤0.01%	4671

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Israel Englander's ELTX Position: Q2 2026 in Review

Israel Englander sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 92,762 shares — an estimated $992K sold.

Israel Englander first reported a position in ELTX in Q1 2021 and held it in 11 quarters. The position peaked at $992K in Q1 2026. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Israel Englander reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 92,762 Elicio Therapeutics shares in Q2 2026, an estimated $992K.
Israel Englander first reported a position in Elicio Therapeutics in Q1 2021 and held it in 11 quarters.
Israel Englander's Elicio Therapeutics position peaked at $992K in Q1 2026.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.